trial

Norwegian Mental Illness Heart Health Study

NCTId NCT07085923

as of 2026-07-01

Add to landscape Monitor this Ask about this

at a glance

— · Recruiting

Enrollment 70 (estimated)

Sponsored by Madeleine Elisabeth Angelsen

Primary completion 2028-06-30

Synthesized from structured facts only — each point cited above.

Design & status

Phase

—

Status

Recruiting

Enrollment

70 (estimated)

Study type

Interventional

Allocation

Randomized

Model

Parallel

Masking

None

Start

2025-09-16

Primary completion

2028-06-30

Eligibility

ALL · 25 Years · 70 Years

Interventions & indications

Drugs

Lifestyle Intervention

Indications

Bipolar Disorder Severe Mental Illness Bipolar Disease Type I Severe Mental Disorder CVD Risk Factors Metabolic Syndrome Overweight and/or Obesity Schizophrenia Cardio Vascular Disease Metabolic Syndrome (MetS)Motor Activity Cardiovascular Diseases

Investigators

Professor Kjetil Retterstøl, Professor, MDPrincipal Investigator

Sites

1 total

Oslo, Norway

Facts & assertions

4 sourced

Enrollment

Phase

Primary Completion Date

2028-06-30

Status

RECRUITING

relationships

The graph out of here

drug

Lifestyle Intervention

drug

lead_sponsor

Madeleine Elisabeth Angelsen

company

indication

Bipolar Disorder

indication

Severe Mental Illness

indication

Bipolar Disease Type I

indication

investigator

Professor Kjetil Retterstøl, Professor, MD

person